Adjuvant Avelumab in Merkel Cell Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

December 19, 2017

Primary Completion Date

April 30, 2026

Study Completion Date

February 18, 2029

Conditions
Stage III Merkel Cell Carcinoma AJCC v8Stage IIIB Merkel Cell Carcinoma AJCC v8Stage IIIA Merkel Cell Carcinoma AJCC v8
Interventions
DRUG

Avelumab

Given IV

OTHER

Peripheral Blood Collection

Correlative studies

OTHER

Placebo

Given IV

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

27599

University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill

33612

Moffitt Cancer Center, Tampa

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

60611

Northwestern University, Chicago

80045

University of Colorado Cancer Center University of Colorado Anschutz Medical Campus, Aurora

92868

University of California Irvine Chao Family Comprehensive Cancer Center, Orange

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

EMD Serono

INDUSTRY

lead

University of Washington

OTHER